new_0222_0487|VOR|Short Name|0|0|total_current_assets|cash_on_hand|inventories_net|net_ppe|goodwill_and_intangible|liabilities|total_current_liabilities|total_long_term_liab|total_deposits|book_value_of_equity|retained_earnings|treasury_stock|ev_revenues|ev_earnings|ev_free_cash_flow|ev_assets|ps_ratio|pe_ratio|price_to_book_value|peg_ratio|debt_equity_ratio|dividend_yield|shareholder_yield_ttm|percent_of_shares_outstanding|receivables|payables|capital_stock|return_on_invested_capital|quality_ratio_fractile|momentum_fractile|market_beta_12_month|sustainable_growth_rate|institutional_investor_ownership_percentage|average_shares_outs_diluted|total_employee_number|eps|shares_outstanding|repurchase_of_capital_stock|ordinary_shares_number|payout_ratio|quick_ratio|normalized_eps|stock_buyback|effective_tax_rate|return_on_equity|net_income_ttm|revenues_ttm|dividend_per_share|revenues|gross_profit|sga_expense|pre_tax_income|net_income|interest_income|price|total_return_price|enterprise_value|average_volume_30|one_year_return
new_0222_0487|VOR|Long Name|1|1|Vor Biopharma Inc Total Current Assets (Quarterly) (USD)|Vor Biopharma Inc Cash and Short Term Investments (Quarterly) (USD)|Vor Biopharma Inc Inventories (Quarterly) (USD)|Vor Biopharma Inc Net PP&E (Quarterly) (USD)|Vor Biopharma Inc Goodwill and Intangibles (Quarterly) (USD)|Vor Biopharma Inc Total Liabilities (Quarterly) (USD)|Vor Biopharma Inc Total Current Liabilities (Quarterly) (USD)|Vor Biopharma Inc Total Long Term Liabilities (Quarterly) (USD)|Vor Biopharma Inc Total Deposits (Quarterly) (USD)|Vor Biopharma Inc Book Value (Quarterly) (USD)|Vor Biopharma Inc Retained Earnings (Quarterly) (USD)|Vor Biopharma Inc Treasury Stock (Quarterly) (USD)|Vor Biopharma Inc EV to Revenues|Vor Biopharma Inc EV to Earnings|Vor Biopharma Inc EV to Free Cash Flow|Vor Biopharma Inc EV to Assets (Quarterly)|Vor Biopharma Inc PS Ratio|Vor Biopharma Inc PE Ratio|Vor Biopharma Inc Price to Book Value|Vor Biopharma Inc PEG Ratio|Vor Biopharma Inc Debt to Equity Ratio|Vor Biopharma Inc Dividend Yield|Vor Biopharma Inc Shareholder Yield (TTM)|Vor Biopharma Inc Percent of Shares Outstanding Short|Vor Biopharma Inc Total Receivables (Quarterly) (USD)|Vor Biopharma Inc Total Payables (Quarterly) (USD)|Vor Biopharma Inc Total Capital Stock (Quarterly) (USD)|Vor Biopharma Inc Return on Invested Capital|Vor Biopharma Inc Quality Ratio Score|Vor Biopharma Inc Momentum Score|Vor Biopharma Inc Beta (1Y)|Vor Biopharma Inc Sustainable Growth Rate (TTM)|Vor Biopharma Inc Institutional Investor Ownership Percentage|Vor Biopharma Inc Average Diluted Shares Outstanding (Quarterly)|Vor Biopharma Inc Total Employees (Annual)|Vor Biopharma Inc EPS Diluted (Quarterly) (USD)|Vor Biopharma Inc Shares Outstanding|Vor Biopharma Inc Repurchase of Capital Stock (Quarterly) (USD)|Vor Biopharma Inc Ordinary Shares Number (Quarterly)|Vor Biopharma Inc Payout Ratio|Vor Biopharma Inc Quick Ratio (Quarterly)|Vor Biopharma Inc Normalized Diluted EPS (Quarterly) (USD)|Vor Biopharma Inc Stock Buybacks (Quarterly) (USD)|Vor Biopharma Inc Effective Tax Rate (TTM)|Vor Biopharma Inc Return on Equity|Vor Biopharma Inc Net Income (TTM) (USD)|Vor Biopharma Inc Revenue (TTM) (USD)|Vor Biopharma Inc Dividend Per Share (Quarterly) (USD)|Vor Biopharma Inc Revenue (Quarterly) (USD)|Vor Biopharma Inc Gross Profit (Quarterly) (USD)|Vor Biopharma Inc SG&A Expense (Quarterly) (USD)|Vor Biopharma Inc Pre-Tax Income (Quarterly) (USD)|Vor Biopharma Inc Net Income (Quarterly) (USD)|Vor Biopharma Inc Net Interest Income (Quarterly) (USD)|Vor Biopharma Inc Price (USD)|Vor Biopharma Inc Total Return Price (USD)|Vor Biopharma Inc Enterprise Value (USD)|Vor Biopharma Inc 30-Day Average Daily Volume|Vor Biopharma Inc 1 Year Price Returns (Daily)
new_0222_0487|VOR|Unit|2|2|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|percent_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_beta|percent_USD_metric|percent_USD_metric|mil_figure_USD_metric|figure_whole_USD_metric|figure_money_USD_per_share_metric|mil_figure_USD_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_money_USD_price|mil_figure_money_USD_metric|figure_USD_metric|percent_USD_metric
new_0222_0487|VOR||4|4|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|daily|quarterly|quarterly|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily
new_0222_0487|VOR||5|5|127.8|127.8|0|127.8|0|127.8|127.8|127.8|0|127.8|127.8|0|0|0|1.44357976654|0|0|0|1.44090909091|0|0|1.44357976654|0|15.347826087|0|127.8|127.8|0|0|0|0|0|0|91.2857142857|91|91.2857142857|30.5555555556|0|127.8|0|0|91.2857142857|91.3333333333|0|0|91.25|0|0|0|0|91.2857142857|91.2857142857|91.2857142857|91.2857142857|1.44357976654|1.44357976654|1.44357976654|1.44298245614|1
new_0222_0487|VOR||6|6|5|5|0|5|0|5|5|5|0|5|5|0|0|0|257|0|0|0|220|0|0|257|0|23|0|5|5|0|0|0|0|0|0|7|3|7|9|0|5|0|0|7|6|0|0|4|0|0|0|0|7|7|7|7|257|257|257|228|4
new_0222_0487|VOR||7|7|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|daily|daily|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|yearly|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|market_daily|market_daily|daily|market_daily|market_daily
new_0222_0487|VOR|201912|201912|201912|7.539|6.466||0.728||2.186|2.186|0||-17.429|-17.887|||||||||||||||0.693|25.069|||||||12.2082||-0.3603|||34.6414|||-0.3189|||||||||0.964|-3.893|-3.893|0.035|||||
new_0222_0487|VOR|202003|202003|202003||||||||||||||||||||||||||||||||||12.2082||-0.7015||||||-0.6429|0||||||||1.707|-7.849|-7.849|0.029|||||
new_0222_0487|VOR|202006|202006|202006||||||||||||||||||||||||||||||||||12.2082||-0.7286||||||-0.6586|0||||||||2.065|-8.04|-8.04|0|||||
new_0222_0487|VOR|202009|202009|202009|65.524|63.604||21.087||25.331|7.6|17.731||-44.142|-45.561|||||||||||||||2.321|107.336|||||||12.2082||-1.1443|||34.6414|||-0.9653|0|||-31.567|||||3.643|-11.785|-11.785|0|||||
new_0222_0487|VOR|202012|202012|202012|49.106|48.539||21.845||27.637|10.207|17.43||-59.065|-61.224|||||||||||||||2.361|107.337|||||||34.6414|76|-0.5148|||34.6414|||-0.4521||||-43.337|||||4.333|-15.663|-15.663|0|||||
new_0222_0487|VOR|202101|202012|202012|||||||||||||||||||||||||||||||||||76||||||||||||||||||||||||
new_0222_0487|VOR|202102|202012|202012|||||||||||||||-42.7091|||||||0||1.1446|||||||||45.9837||||37.12||||||||||||||||||44.96|44.96|1727.7122||
new_0222_0487|VOR|202103|202103|202103|266.265|262.567||22.533||25.752|8.631|17.121||267.187|-74.947||||-25.1167||||5.9314|||0||3.9706||2.406|0.004|||||||22.264||-0.67|36.77||36.77|||-0.67|-189.199|||-49.211|||||4.789|-13.723|-13.723|0.007|43.1|43.1|1322.22|320345.5|
new_0222_0487|VOR|202104|202103|202103|||||||||||||||-14.889||||3.9162|||0||4.2301|||||||||||||37.1316||||||||||||||||||28.18|28.18|783.8015|204570.5667|
new_0222_0487|VOR|202105|202103|202103|||||||||||||||-9.8951||||2.9323|||0||4.1761|||||||||||||||||||||||||||||||21.1|21.1|520.9098|121840.7333|
new_0222_0487|VOR|202106|202106|202106|249.265|244.634||22.208||25.035|8.304|16.731||250.108|-93.317||||-7.2376||||2.7505|||0||4.3063||2.369|0.004|||||||36.8431|109|-0.5|36.8854||36.8854|||-0.5|0|||-59.541|||||5.41|-18.37|-18.37|0.01|18.65|18.65|443.2787|138667.5333|
new_0222_0487|VOR|202107|202106|202106|||||||||||||||-3.5458||||1.8464|||0||4.5803|||||||||||||||||||||||||||||||12.52|12.52|217.1712|151822.8667|
new_0222_0487|VOR|202108|202106|202106|||||||||||||||-4.9149||||2.1817|||0||4.3445|||||||||||||37.1446||||||||||||||||||14.69|14.69|301.0202|143517.1667|
new_0222_0487|VOR|202109|202109|202109|232.072|225.968||22.006||25.675|9.21|16.465||232.957|-111.871||||-5.1082||||2.4916|||0||4.9734||1.957|0.004|||||||36.9343|122|-0.5|37.0183||37.0183|||-0.5|0|||-66.31|||||5.677|-18.554|-18.554|0.048|15.68|15.68|354.4789|187490.5667|
new_0222_0487|VOR|202110|202109|202109|||||||||||||||-5.1349||||2.4996|||0||4.9038|||||||||||||||||||||||||||||||15.73|15.73|356.3299|98169.7333|
new_0222_0487|VOR|202111|202109|202109|||||||||||||||-2.9448||||1.8472|||0||4.953|||||||||||||37.2895||||||||||||||||||11.54|11.54|204.3528|89427.5333|
new_0222_0487|VOR|202112|202112|202112|||||||||||||||-2.9878||||1.86|||0||4.8097|||||||||||||||||||||||||||||||11.62|11.62|207.336|127450.1667|
new_0222_0487|VOR|202201|202112|202112|||||||||||||||-1.1769||||1.3206|||0||5.1982|||||||||||||||||||||||||||||||8.25|8.25|81.6704|93516.0667|
new_0222_0487|VOR|202202|202112|202112|||||||||||||||-1.365||||1.3766|||0|||||||||||||||||||||||||||||||||8.6|8.6|94.7217|79078.9333|-79.944